ArticleLeukemia2011
Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?
Article in Leukemia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of ropeginterferon alfa-2b in the treatment of polycythemia vera: a systematic review with single arm meta-analysis.Annals of hematology · 2025Pooled it
- Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.International journal of hematology · 2018Trial
- The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.Annals of hematology · 2017Trial
- Trial
- Epigenetic Modification of Cytosines in Hematopoietic Differentiation and Malignant Transformation.International journal of molecular sciences · 2023Review
- Cladribine treatment for Erdheim-Chester disease involving the central nervous system and concomitant polycythemia vera: A case report.Journal of clinical and experimental hematopathology : JCEH · 2018Article
- Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.JCI insight · 2018Article
- Evaluation of the dose and efficacy of ruxolitinib in Japanese patients with myelofibrosis.International journal of hematology · 2018Article
- How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.Current hematologic malignancy reports · 2016Review
- Epigenetics of hematopoiesis and hematological malignancies.Genes & development · 2016Review
- Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.Leukemia · 2015Article
- Current and future treatment options for polycythemia vera.Annals of hematology · 2015Review
- Article
- JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden.PloS one · 2015Article
- TET proteins and 5-methylcytosine oxidation in hematological cancers.Immunological reviews · 2015Review
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.Leukemia · 2013Article
- AKT is a therapeutic target in myeloproliferative neoplasms.Leukemia · 2013Article
- Myeloid malignancies: mutations, models and management.BMC cancer · 2012Review
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
21750560What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.